Welcome to our dedicated page for BeyondSpring SEC filings (Ticker: BYSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BeyondSpring Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on cancer therapies, including Plinabulin development, financial results and capital structure. Its Form 10-K and Form 8-K disclosures cover audited consolidated financial statements, quarterly and annual operating results, clinical-program updates, and risk and business information tied to oncology development.
Current reports also record material agreements, registered offerings of ordinary shares, SEED Therapeutics financing and ownership disclosures, and shareholder-vote results from annual meetings. These filings describe governance actions, securities issuances, registration-statement use and other material events affecting BeyondSpring’s public-company reporting.
Decheng Capital entities reported multiple small open-market sales of BeyondSpring Inc. (BYSI) ordinary shares between August 26 and August 28, 2025. Fund III sold 2,000 shares on 08/26/2025 at a weighted-average price of $1.79, 1,300 shares on 08/27/2025 at $1.78, and 809 shares on 08/28/2025 at $1.81; those disposals reduced Fund III's beneficial holding to 1,909,625 shares. The filing discloses additional indirect holdings: Fund II holds 1,617,409 shares and Decheng Global Healthcare (Master) LP holds 891,734 shares. The reporting chain shows common control through Decheng Capital management entities and Dr. Xiangmin (Xiangmin) Cui as manager, with standard disclaimers of beneficial ownership by general partners except for pecuniary interest. Footnotes state the prices are weighted averages across multiple transactions within disclosed price ranges.
Decheng Capital entities and Dr. Xiangmin Cui reported a series of open-market sales of BeyondSpring Inc. (BYSI) ordinary shares in August 2025. Decheng Capital China Life Sciences USD Fund III, L.P. sold a total of 5,710 ordinary shares across 08/21/2025–08/25/2025 at weighted average prices of approximately $1.79, $1.75, and $1.77, leaving Fund III with 1,913,734 shares beneficially owned. Related Decheng vehicles also report indirect holdings of 1,617,409 and 891,734 shares respectively. All holdings are reported as indirect and the filings disclose customary disclaimers of direct beneficial ownership by the general partners and manager.
Decheng Capital entities and Dr. Xiangmin Cui reported insider sales of BeyondSpring Inc. (BYSI) ordinary shares on August 18-20, 2025. The filing shows three reported dispositions totaling 54,728 shares sold by Decheng Capital China Life Sciences USD Fund III, L.P. at weighted average prices of $2.03 (47,668 shares), $1.77 (3,604 shares) and $1.74 (3,456 shares). After these transactions, Fund III reported beneficial ownership of 1,919,444 shares (indirect). Related Decheng entities also reported indirect holdings of 1,617,409 and 891,734 shares respectively. The filing includes standard footnotes explaining weighted average prices and the indirect ownership through GP and manager relationships.
Decheng Capital entities and Dr. Cui reported Form 4 transactions in BeyondSpring Inc. (BYSI). On 08/14/2025, Decheng Capital China Life Sciences USD Fund III, L.P. sold 2,000 ordinary shares at a weighted average price of $2.00–$2.01, reducing its reported beneficial ownership to 1,977,072 shares. On 08/15/2025 the same Fund sold 2,900 ordinary shares at a weighted average price of $2.00–$2.01, reducing its reported beneficial ownership to 1,974,172 shares. The filing also discloses indirect beneficial holdings of 1,617,409 shares by Decheng Capital China Life Sciences USD Fund II, L.P. and 891,734 shares by Decheng Capital Global Healthcare Fund (Master), LP. Signatures indicate reporting by fund GPs and Xiangmin Cui.
BeyondSpring Inc. Schedule 13G/A reports beneficial ownership by Decheng-related funds and individuals as of June 30, 2025. Dr. Xiangmin Cui and affiliated Decheng entities collectively hold disclosed stakes through multiple Cayman-structured funds and management companies. Individually reported holdings include 1,979,072 shares by Decheng Capital China Life Sciences USD Fund III (4.9%), 1,617,409 shares by Fund II (4.0%), and 935,000 shares by Decheng Capital Global Healthcare Fund (2.3%), for a total beneficial ownership by Dr. Cui of 4,531,481 shares, representing 11.2% of outstanding ordinary shares based on 40,316,320 shares outstanding.
The filing states voting and dispositive power is shared among GP entities and identifies Dr. Cui as manager and ultimate beneficial owner of the reporting entities. The statement certifies the holdings were not acquired to change or influence control.
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on its lead asset Plinabulin and a TPD platform carried through SEED. As of June 30, 2025 the consolidated balance sheet shows $31.0 million in total assets and $48.6 million in total liabilities, resulting in a $17.5 million shareholders' deficit (including noncontrolling interests). Cash and cash equivalents from continuing operations increased to $9.544 million.
Operationally, the company reported a consolidated net loss of $4.65 million for the quarter ended June 30, 2025 and a $3.48 million net loss for the six months. For the six months ended June 30, 2025, however, net income attributable to BeyondSpring Inc. was $2.671 million, which reflects a $6.986 million gain recognized on the first closing of the sale of subsidiary interests in SEED. The company completed a first closing that generated $7.354 million of cash proceeds and recorded gross proceeds from the multi-tranche sale agreements of approximately $35.418 million.
Cash flow activity shows $10.07 million used in operating activities and $17.15 million provided by investing activities (including maturities of short-term investments and proceeds from the SEED sale), producing a $7.08 million net increase in cash for the six months. Significant off-balance-sheet and contract items disclosed include $31.039 million upfront consideration received under the Hengrui collaboration that remains recorded as deferred revenue and a full valuation allowance on deferred tax assets with $4.573 million of gross unrecognized tax benefits.
BeyondSpring Inc. filed a current report to note that it released a press release with its financial results for the quarter ended June 30, 2025. The company furnished this press release as an exhibit, meaning it is made available for investors’ information but is not treated as part of the company’s formally "filed" financial statements under securities laws. The filing also confirms that BeyondSpring’s ordinary shares continue to trade on The NASDAQ Stock Market under the symbol BYSI.
Decheng Capital-affiliated entities reported a series of open-market sales of BeyondSpring Inc. (BYSI) ordinary shares between 06/17/2025 and 08/04/2025. The Form 4 shows multiple dispositions totaling 394,436 shares sold across the reported dates at prices ranging from $3.23 down to $2.18. Footnotes note weighted-average prices and price ranges for specific blocks ($3.10–$3.34, $3.05–$3.27, $3.06–$3.19) and state the reporters will provide per-price details on request. Despite these sales, the filing shows that Decheng Capital China Life Sciences USD Fund III, L.P. continues to beneficially own 1,979,072 shares (indirect), and related Decheng entities and managers disclaim direct ownership except to the extent of pecuniary interest.
Decheng Capital and related funds disclosed initial beneficial ownership in BeyondSpring Inc. (BYSI). Three Decheng-managed funds report indirect holdings of 1,979,072, 1,903,579 and 1,000,000 ordinary shares respectively. The filings indicate indirect ownership through general partner entities and identify Dr. Xiangmin Cui as manager with disclaimers of ownership except for pecuniary interest. No derivative securities are reported.